Get started
Author

Turçin Saridogan

Observed name: Turcin Saridogan
ORCID: 0000-0001-8659-445X
Observed ORCID: 0000-0001-8659-445X
OpenAlex ID: A5017702104
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer
2021 · Kurt W. Evans, Erkan Yuca, et al. · Cancer Research · 178
PDF
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment
2021 · Hua Sun, Song Cao, et al. · Nature Communications · 109
PDF
Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer
2021 · Ming Zhao, Stephen Scott, et al. · Clinical Cancer Research · 63
Neoadjuvant Immune Checkpoint Inhibitor Therapy for Patients With Microsatellite Instability-High Colorectal Cancer: Shedding Light on the Future
2023 · Ibrahim Halil Sahin, Janie Zhang, et al. · JCO Oncology Practice · 32
PDF
Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine
2022 · Ruveyda Ayasun, Turcin Saridogan, et al. · Clinical Colorectal Cancer · 22
Investigating the WNT and TGF-beta pathways alterations and tumor mutation burden in young-onset colorectal cancer
2024 · Morgan Ferrell, Deniz Can Guven, et al. · Scientific Reports · 21
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer
2023 · Turcin Saridogan, Argun Akcakanat, et al. · Scientific Reports · 19
PDF
Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine
2024 · Ibrahim Halil Sahin, Turcin Saridogan, et al. · JCO Oncology Practice · 14
Predictive biomarkers for immune checkpoint inhibition for patients with colorectal cancer: a comprehensive review
2025 · Ibrahim Halil Sahin, Turcin Saridogan, et al. · Immunotherapy · 12
Dispersed DNA variants underlie hearing loss in South Florida’s minority population
2023 · LéShon Peart, Joanna Gonzalez, et al. · Human Genomics · 11
PDF
Natural Language Processing–Assisted Literature Retrieval and Analysis for Combination Therapy in Cancer
2022 · Jia Zeng, Christian X. Cruz Pico, et al. · JCO Clinical Cancer Informatics · 10
The Role of Circulating Tumor DNA for Management of Patients With Rectal Cancer: Challenges and Opportunities
2024 · Ibrahim Halil Sahin, Rami Yanes, et al. · The Cancer Journal · 5
Shedding Light on the Prognostic and Predictive Value of Circulating Tumor DNA for Management of Patients with Early-Stage Colon Cancer
2025 · Rami Yanes, Turcin Saridogan, et al. · Technology in Cancer Research & Treatment · 4
Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma
2024 · Anath Lionel, Sushanth Gouni, et al. · Blood · 1
PDF
Abstract C016: Oxidative phosphorylation is a metabolic vulnerability in chemotherapy resistant triple negative breast cancer
2019 · Kurt Evans, Stacy Moulder, et al. · Molecular Cancer Therapeutics · 1
Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy
2025 · Anath Lionel, Sushanth Gouni, et al. · Blood
PDF
Author response for "Shedding Light on the Prognostic and Predictive Value of Circulating Tumor DNA for Management of Patients with Early-Stage Colon Cancer"
2024 · Rami Yanes, Turcin Saridogan, et al. · Publons reviews and discussion
Data from Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer
2024 · Ming Zhao, Stephen Scott, et al.
Table S1, Figure S1,Table S2, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8, Figure S9 from Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer
2024 · Ming Zhao, Stephen Scott, et al.
Supplementary Data from Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer
2024 · Ming Zhao, Stephen Scott, et al.
Supplementary Data from Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer
2023 · Kurt W. Evans, Erkan Yuca, et al.
Data from Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer
2023 · Kurt W. Evans, Erkan Yuca, et al.
Abstract P5-08-12: Efficacy of futibatinib, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in breast cancer models with FGFR alterations
2022 · Turcin Saridogan, Argun Akcakanat, et al. · Cancer Research
Abstract B003: Combinatorial therapies of neratinib for HER2-amplified cancer
2019 · Ming Zhao, Stephen Scott, et al. · Molecular Cancer Therapeutics
Works count: 24
Citation count: 502
H-index: 10
I10-index: 11
Year
Topic
Type